Plus Therapeutics Data Suggests 40% Cost Reduction for Leptomeningeal Metastases Treatment
Event summary
- Plus Therapeutics will present data at ISPOR 2026 showing CNSide® assay may reduce leptomeningeal metastases (LM) healthcare costs by 40%.
- Cost savings driven by earlier therapeutic intervention, reduced hospitalizations, and improved treatment precision.
- Late-stage LM diagnosis costs average $20,000 per inpatient admission, with total monthly costs exceeding $100,000.
- Presentation co-authored with Harvard T.H. Chan School of Public Health, utilizing real-world data and healthcare claims databases.
The big picture
The presentation underscores the growing importance of health economics data in diagnostic adoption, particularly for rare but costly conditions like leptomeningeal metastases. Plus Therapeutics' focus on both cost reduction and targeted radiotherapeutics aligns with broader industry trends toward value-based healthcare. The $17.6M CPRIT grant and NIH support highlight the strategic importance of LM treatment innovation.
What we're watching
- Commercialization Pace
- Whether Plus Therapeutics can accelerate CNSide adoption among payers and health systems following these cost findings.
- Clinical Trial Progress
- The pace at which REYOBIQ™ trials (ReSPECT-GBM, ReSPECT-LM, ReSPECT-PBC) advance, particularly with CPRIT and NIH funding.
- Payer Acceptance
- How insurers respond to the economic impact data in coverage and reimbursement decisions for CNSide.
Related topics